Is SpyGlass Pharma Inc halal to invest in?

According to Musaffa's Shariah screening methodology, SpyGlass Pharma Inc (SGP) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is SpyGlass Pharma Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes SpyGlass Pharma Inc using these criteria to determine its compliance status.

Can Muslims buy shares of SpyGlass Pharma Inc?

Muslim investors may consider investing in SpyGlass Pharma Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is SpyGlass Pharma Inc classified as NOT HALAL?

Musaffa determines the Shariah status of SpyGlass Pharma Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for SpyGlass Pharma Inc updated?

The Shariah compliance status of SpyGlass Pharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like SpyGlass Pharma Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of SpyGlass Pharma Inc?

You can check the latest Shariah compliance status of SpyGlass Pharma Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SGP Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 30, 2026

Report Source: 2025 Annual Report

SpyGlass Pharma Inc. Stock Analysis SGP

United States Health Care Small Cap Report: 2025 Annual

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

Key Statistics of SpyGlass Pharma Inc (SGP)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$21.90$24.77

Today's Open

$21.90

Volume

34.91K

P/E Ratio (TTM)

52 Week Range

$20.15$32.44

Market Cap

815.94M

Avg. Volume

57.00K

Dividend Yield

Financial Metrics & Statements of SpyGlass Pharma Inc (SGP)

FAQ's for SpyGlass Pharma Inc (SGP)

According to Musaffa’s Shariah screening methodology, SpyGlass Pharma Inc (SGP) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.